

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	He) GROUP ART UNIT:	1617
)	
SERIAL NO.:	10/008,223) CONFIRMATION NO.:	4333
)	
EXAMINER:	Webman) ATTORNEY DOCKET	3409/1/US
) NO.:	(PC31297)
FILED:	December 5, 2001)	
TITLE:	RAPIDLY DISPERSING PHARMACEUTICAL COMPOSITION		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 15, 2007

RESPONSE TO OFFICE ACTION

Sir:

In response to the Office action dated January 17, 2007, the time for response to which has been extended by two months, please enter the following remarks.

Claims 18, 20, 21, 23-37, and 39-53 are currently pending and stand rejected under 35 U.S.C. §103(a) as being unpatentable over Bolt et al., European Patent No. 396 335 ("Bolt") in view of Harrison et al., U.S. Patent No. 6,086,909 ("Harrison"). Reconsideration of this rejection is respectfully requested.

The Office asserts that "the chewable tablets disclosed by Bolt et al., can either be swallowed or chewed before swallowing, which does not necessarily involve disintegration in the mouth."

Respectfully, Applicants disagree with this assertion. The Office has not shown that Bolt's chewable tablet can be swallowed whole. Bolt clearly did not intend for the chewable tablets described to be swallowed whole, and nothing in Bolt indicates that the chewable tablets described therein can be swallowed whole. Bolt clearly